MARKET

CYTO

CYTO

Altamira Therapeutics Ltd
NASDAQ

Real-time Quotes | Nasdaq Last Sale

2.160
-0.090
-4.00%
After Hours: 2.140 -0.02 -0.93% 17:19 09/17 EDT
OPEN
2.180
PREV CLOSE
2.250
HIGH
2.262
LOW
2.105
VOLUME
203.97K
TURNOVER
--
52 WEEK HIGH
6.60
52 WEEK LOW
0.7255
MARKET CAP
28.16M
P/E (TTM)
-1.4439
1D
5D
1M
3M
1Y
5Y
Altamira Therapeutics to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
HAMILTON, BERMUDA / ACCESSWIRE / September 9, 2021 / Altamira Therapeutics Ltd. (NASDAQ:CYTO), a company dedicated to addressing unmet medical needs through RNA therapeutics, allergy and viral infection protection, and inner ear therapeutics, today announc...
ACCESSWIRE · 09/09 12:30
Altamira Therapeutics Provides Business Update and Reports First Half 2021 Financial Results
(NASDAQ:CYTO) ("Altamira" or the "Company"), a company dedicated to addressing unmet medical needs through RNA therapeutics, allergy and viral infection protection, and inner ear therapeutics, today provided a business update and announced first half 2021 ...
ACCESSWIRE · 09/08 12:30
Altamira Therapeutics Reports Effects Of Bentrio Nasal Spray Against Influenza A Virus; Says Showed 'Significant reduction of viral titer in human nasal epithelium model both in prevention and treatment of influenza infection '
Significant reduction of viral titer in human nasal epithelium model both in prevention and treatment of influenza infection (p<0.01) New data demonstrate protective effects in viral infections beyond
Benzinga · 08/06 13:01
Altamira Therapeutics Reports Protective Effects of Bentrio(TM) Nasal Spray Against Influenza A Virus (H1N1)
* Significant reduction of viral titer in human nasal epithelium model both in prevention and treatment of influenza infection (p<0.01) * New data demonstrate protective effects in viral infections beyond SARS-CoV-2HAMILTON, BERMUDA / ACCESSWIRE / August 6...
ACCESSWIRE · 08/06 13:00
Altamira Therapeutics Announces Launch of Website Dedicated to Bentrio(TM) Nasal Spray
HAMILTON, BERMUDA / ACCESSWIRE / August 3, 2021 / Altamira Therapeutics Ltd. (NASDAQ:CYTO), a company dedicated to addressing unmet medical needs through RNA therapeutics, allergy and viral infection protection, and inner ear therapeutics, today announced ...
ACCESSWIRE · 08/03 13:01
Auris Medical launches new corporate website
Auris Medical Holding (EARS) announces the launch of its newly-designed corporate website www.aurismedical.com. "...the new website reflects the company’s recent strategic move into RNA therapeutics, while highlighting the exciting prospects for its
Seekingalpha · 07/16 13:07
Auris Medical Announces Launch of New Corporate Website
Hamilton, Bermuda, July 15, 2021 – Auris Medical Holding Ltd. (NASDAQ: EARS), a company dedicated to addressing unmet medical needs through RNA therapeutics, allergy and viral infection protection, and inner ear therapeutics, today announced the launch of ...
GlobeNewswire · 07/16 13:00
Auris Medical's Bentrio Nasal Spray Shows Encouraging Preclinical Action In Prevention, Mitigation Of COVID-19
Benzinga · 07/14 15:40
More
Forecast
Actual (K USD)
Estimate (K USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of CYTO. Analyze the recent business situations of Altamira Therapeutics Ltd through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 1 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average CYTO stock price target is 14.69 with a high estimate of 14.69 and a low estimate of 14.69.
EPS
Institutional Holdings
Institutions: 20
Institutional Holdings: 1.43M
% Owned: 10.97%
Shares Outstanding: 13.04M
TypeInstitutionsShares
Increased
4
26.49K
New
4
10.88K
Decreased
3
68.23K
Sold Out
8
159.79K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.49%
Pharmaceuticals & Medical Research
-0.10%
Key Executives
Chairman/Chief Executive Officer/Director
Thomas Meyer
Non-Executive Vice Chairman
James Healy
Chief Financial Officer/Primary Contact
Hernan Levett
General Counsel
Anne Zoller
Other/IR Contact Officer
Cindy McGee
Other
Andrea Braun
Other
Thomas Jung
Other
Bettina Stubinski
Director
Mats Blom
Director
Alain Munoz
Non-Executive Independent Director
Oliver Kubli
Non-Executive Independent Director
Berndt Modig
Non-Executive Independent Director
Armando Anido
Non-Executive Independent Director
Calvin Roberts
Non-Executive Independent Director
Wolfgang Arnold
No Data
About CYTO
Auris Medical Holding AG is a Switzerland-based biotechnologyompany focused on developing and commercializing therapeutics and medical devices for neurotology, rhinology and allergy and central nervous system (CNS) disorders.The Company is active in active in three areas such as: the development of oligonucleotides for extrahepatic therapeutic targets - OligoPhore platform; nasal sprays for protection against airborne viruses and allergens Bentrio or the treatment of vertigo AM-125 ; he development of therapeutics for intratympanic treatment of tinnitus Keyzilen or hearing loss Sonsuvi .

Webull offers kinds of Altamira Therapeutics Ltd stock information, including NASDAQ:CYTO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CYTO stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CYTO stock methods without spending real money on the virtual paper trading platform.